Singapore, June 16 -- South Korea-based Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), has announced the launch ofSamsung Organoids- advanced drug screening services to support clients in drug discovery and development.

Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. Organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction.

Samsung Organoidssupportprecision screening to predict patient responses, streamline preclinical developme...